Metagenomi (MGX) News Today $1.41 +0.15 (+11.90%) Closing price 04:00 PM EasternExtended Trading$1.43 +0.02 (+1.42%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Metagenomi, Inc. Common Stock (MGX) Latest After Hours TradesMarch 31, 2025 | nasdaq.comBiotech stocks slide as Marks resignation seen being negative for sectorMarch 31, 2025 | markets.businessinsider.comAnalysts Issue Forecasts for Metagenomi FY2025 EarningsMetagenomi, Inc. (NASDAQ:MGX - Free Report) - Research analysts at Chardan Capital issued their FY2025 earnings estimates for shares of Metagenomi in a research report issued on Monday, March 24th. Chardan Capital analyst G. Livshits anticipates that the company will post earnings of ($1.47) perMarch 28, 2025 | marketbeat.comChardan Capital Forecasts Metagenomi FY2025 EarningsMarch 28, 2025 | americanbankingnews.comBullish: Analysts Just Made A Significant Upgrade To Their Metagenomi, Inc. (NASDAQ:MGX) ForecastsMarch 27, 2025 | uk.finance.yahoo.comMetagenomi (NASDAQ:MGX) Given New $20.00 Price Target at Wells Fargo & CompanyWells Fargo & Company dropped their target price on shares of Metagenomi from $25.00 to $20.00 and set an "overweight" rating on the stock in a report on Tuesday.March 19, 2025 | marketbeat.comMetagenomi, Inc.: Metagenomi Reports Business Updates and Full Year 2024 Financial ResultsMarch 19, 2025 | finanznachrichten.deMetagenomi (MGX) Expected to Announce Earnings on WednesdayMetagenomi (NASDAQ:MGX) will be releasing earnings before the market opens on Wednesday, March 26, Financial Modeling Prep reports.March 19, 2025 | marketbeat.comMetagenomi Faces Legal Battle Over Alleged Misleading Statements in Moderna CollaborationMarch 19, 2025 | tipranks.comMetagenomi, Inc. Reports 2024 Financial Results and Pipeline ProgressMarch 19, 2025 | tipranks.comMetagenomi files $250M mixed securities shelfMarch 18, 2025 | markets.businessinsider.comMetagenomi (NASDAQ:MGX) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPSMetagenomi (NASDAQ:MGX - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.01). Metagenomi had a negative net margin of 134.27% and a negative return on equity of 43.23%.March 18, 2025 | marketbeat.comMetagenomi Reports 2024 Financial Results and UpdatesMarch 17, 2025 | tipranks.comMetagenomi Reports Business Updates and Full Year 2024 Financial ResultsMarch 17, 2025 | globenewswire.comMetagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) SystemsMarch 13, 2025 | globenewswire.comThis Emirati Prince Controls Four Times Elon Musk's Wealth and He’s Going All-In on AIFebruary 27, 2025 | msn.comGood Life Advisors LLC Acquires New Shares in Metagenomi, Inc. (NASDAQ:MGX)Good Life Advisors LLC bought a new position in Metagenomi, Inc. (NASDAQ:MGX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 125,000 shares of the company's stock, valued at approximately $451,000. Good Life Advisors LLC ownedFebruary 21, 2025 | marketbeat.comMetagenomi, Inc. (NASDAQ:MGX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMetagenomi, Inc. (NASDAQ:MGX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have given a buy rFebruary 18, 2025 | marketbeat.comShort Interest in Metagenomi, Inc. (NASDAQ:MGX) Rises By 21.7%Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) was the recipient of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 2,640,000 shares, a growth of 21.7% from the January 15th total of 2,170,000 shares. Currently, 14.1% of the shares of the company are short sold. Based on an average daily trading volume, of 2,300,000 shares, the short-interest ratio is presently 1.1 days.February 16, 2025 | marketbeat.comPeapod Lane Capital LLC Takes $1.27 Million Position in Metagenomi, Inc. (NASDAQ:MGX)Peapod Lane Capital LLC purchased a new position in Metagenomi, Inc. (NASDAQ:MGX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 351,213 shares of the company's stock,February 13, 2025 | marketbeat.comMetagenomi to Present at TD Cowen's 45th Annual Health Care ConferenceFebruary 11, 2025 | globenewswire.comTotus Medicines Appoints Simon Harnest As CFOJanuary 28, 2025 | markets.businessinsider.comNeutral On Metagenomi's Promising Yet Highly Speculative Gene Editing PotentialJanuary 28, 2025 | seekingalpha.comBrokerages Set Metagenomi, Inc. (NASDAQ:MGX) Price Target at $16.67Shares of Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the seven analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have assignedJanuary 27, 2025 | marketbeat.comMetagenomi, Inc. (NASDAQ:MGX) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) have been given an average rating of "Moderate Buy" by the seven ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have assigned a buyJanuary 24, 2025 | marketbeat.comPromising Outlook for Metagenomi, Inc.: Strategic Collaborations and Technological Advancements Drive Buy RatingJanuary 17, 2025 | markets.businessinsider.comMetagenomi advances gene editing therapies into 2025January 16, 2025 | msn.comMetagenomi outlines anticipated 2025 milestonesJanuary 16, 2025 | msn.comMetagenomi Expands Leadership and Showcases InnovationsJanuary 16, 2025 | tipranks.comMetagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated MilestonesJanuary 16, 2025 | globenewswire.comMetagenomi appoints Eric Bjerkholt to board of directorsJanuary 16, 2025 | markets.businessinsider.comMetagenomi Announces New Appointment to its Board of DirectorsJanuary 15, 2025 | globenewswire.comMetagenomi, Inc.'s (NASDAQ:MGX) market cap dropped US$12m last week; individual investors who hold 33% were hit as were institutionsJanuary 15, 2025 | finance.yahoo.comGeode Capital Management LLC Has $734,000 Position in Metagenomi, Inc. (NASDAQ:MGX)Geode Capital Management LLC increased its holdings in shares of Metagenomi, Inc. (NASDAQ:MGX - Free Report) by 105.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 338,031 shares of the company's stock after acquiringJanuary 12, 2025 | marketbeat.comMetagenomi to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | globenewswire.comMetagenomi, Inc. (NASDAQ:MGX) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seven analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the comDecember 30, 2024 | marketbeat.comShort Interest in Metagenomi, Inc. (NASDAQ:MGX) Increases By 445.1%Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) was the recipient of a large growth in short interest in December. As of December 15th, there was short interest totalling 1,480,000 shares, a growth of 445.1% from the November 30th total of 271,500 shares. Currently, 7.9% of the company's stock are sold short. Based on an average daily trading volume, of 1,760,000 shares, the days-to-cover ratio is presently 0.8 days.December 26, 2024 | marketbeat.comMetagenomi’s Gene Editing Breakthroughs and FVIII Advancements Propel Buy RatingDecember 12, 2024 | markets.businessinsider.com2 ‘Monster’ Stocks to Snap Up Before 2025December 12, 2024 | msn.comUpgraded Buy Rating for Metagenomi, Inc. Driven by Promising Hemophilia A Program and Strong Financial PositionDecember 12, 2024 | markets.businessinsider.comMetagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV”December 11, 2024 | globenewswire.comHC Wainwright Issues Positive Forecast for Metagenomi (NASDAQ:MGX) Stock PriceHC Wainwright lifted their price objective on shares of Metagenomi from $7.00 to $14.00 and gave the company a "buy" rating in a report on Tuesday.December 10, 2024 | marketbeat.comMetagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual MeetingDecember 9, 2024 | globenewswire.comMetagenomi, Inc. (NASDAQ:MGX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) have received an average rating of "Moderate Buy" from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and six have given a buy rating toDecember 5, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Metagenomi, Inc. - MGXNovember 25, 2024 | prnewswire.comMGX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Metagenomi, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitNovember 25, 2024 | globenewswire.comMGX DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Metagenomi, Inc. Investors to Secure Counsel Before Important November 25 Deadline in Securities Class Action – MGXNovember 25, 2024 | globenewswire.comMGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Fraud Lawsuit with the Schall Law FirmNovember 25, 2024 | prnewswire.comFINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MetagenomiNovember 25, 2024 | businesswire.comWhat is HC Wainwright's Forecast for Metagenomi Q4 Earnings?Metagenomi, Inc. (NASDAQ:MGX - Free Report) - Equities researchers at HC Wainwright raised their Q4 2024 earnings estimates for shares of Metagenomi in a report issued on Thursday, November 21st. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($0.52November 25, 2024 | marketbeat.com Remove Ads Get Metagenomi News Delivered to You Automatically Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter. Email Address MGX Media Mentions By Week MGX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MGX News Sentiment▼0.270.61▲Average Medical News Sentiment MGX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MGX Articles This Week▼46▲MGX Articles Average Week Remove Ads Get Metagenomi News Delivered to You Automatically Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Corvus Pharmaceuticals News Today Foghorn Therapeutics News Today Ocugen News Today INmune Bio News Today Eledon Pharmaceuticals News Today Y-mAbs Therapeutics News Today Protalix BioTherapeutics News Today Inhibrx News Today Checkpoint Therapeutics News Today Tevogen Bio News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MGX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metagenomi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MGX Stock Free MGX Stock Alerts